Zoledronate (Zometa™) is exclusively administered intravenously.
Its indications are :
Since it is slowly eliminated from the blood, the usual dosage is relatively low (about 4 to 8 mg per cure which can be renewed every 4 weeks). In malignant hypercalcaemia, strict monitoring is required. Infusion is short (about 30 minutes).
During infusion, fever may be observed (delayed fever can also occur ) as well as flu-like syndrome, local reactions, bone pains, myalgias. All of these side effects are generally mild.